Gurston Nyquist, MD
Otolaryngology · Philadelphia, PANPI 1699822536
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,682 of the $17,947 with a category attached, or 87.4%. 11 manufacturers reported payments, led by Sanofi at 57.4% of the total. 2025 is the largest year on record at $15,393, more than ten times the $14 reported in 2019. Among otolaryngology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $560.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$10K
- Regeneron$6K
- Medtronic$531
- Stryker$380
- Amgen$125
- Acclarent, Inc$84
- plus $125 from 5 others
Across 20 payments — averaging $3560.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$49K
- Sanofi US Services Inc.$22K
What the payments were for
- Consulting fees$15,68287%
- Travel & lodging$4783%
- Food & beverage$1,78710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 14 | $10,298 |
| Regeneron | 3 | $6,404 |
| Medtronic | 3 | $531 |
| Stryker | 3 | $380 |
| Amgen | 1 | $125 |
| Acclarent, Inc | 3 | $84 |
| Neurent Medical Limited | 1 | $43 |
| Aerin Medical Inc. | 1 | $26 |
| Integra Lifesciences Corporation | 1 | $26 |
| Phadia US Inc. | 1 | $15 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,947 in reported general payments places this provider in the 90th percentile of 456 otolaryngology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 42 | $155,568 |
| Dupixent SyringeDupilumab | 11 | $40,263 |
| Azelastine Hcl | 231 | $4,020 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 16 | $2,865 |
| Ipratropium Bromide | 100 | $1,997 |
| Fluticasone Propionate | 170 | $1,295 |
| Mometasone Furoate | 20 | $1,006 |
| Fluocinolone Acetonide Oil | 18 | $829 |
| Cefdinir | 32 | $495 |
| Montelukast Sodium | 24 | $357 |
| Omeprazole | 26 | $165 |
| Doxycycline Monohydrate | 21 | $134 |
| Ciprofloxacin Hcl | 18 | $116 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $79 |
| Azithromycin | 15 | $73 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Philadelphia
- Nancy SnydermanPhiladelphia$4.5M
- David KennedyPhiladelphia$603K
- James PalmerPhiladelphia$331K
- Mathew NagorskyPhiladelphia$95K
- Noam CohenPhiladelphia$76K
- Nithin AdappaPhiladelphia$72K
- Steven CannadyPhiladelphia$33K
- David CognettiPhiladelphia$30K
- John KrousePhiladelphia$30K
- Soo AbboudPhiladelphia$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.